Physician profile
Kenneth Alan Gustke
NPI 1144225855
$5,222,758.46
in general payments reported to CMS, 2019-2025
16 companies · $884K in 2025
The $884K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621K · 2020: $672K · 2021: $776K · 2022: $660K · 2023: $752K · 2024: $857K · 2025: $884K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $2.5M · Consulting Fee: $22K · Food and Beverage: $1,301 · Travel and Lodging: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $2,469,600.00 |
| Consulting Fee | $21,775.00 |
| Food and Beverage | $1,301.21 |
| Travel and Lodging | $788.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $5,193,521.30 | 2019-2025 | Mako |
| Orthosensor INC. | $26,331.63 | 2019 | |
| Zimmer Biomet Holdings, INC. | $1,142.88 | 2019-2024 | Persona, Mymobility Platform |
| Total Joint Orthopedics, INC. | $312.12 | 2019-2021 | |
| Innovation Technologies INC | $269.15 | 2021-2022 | |
| Solventum Corporation | $254.95 | 2024-2025 | Prevena, V.A.C.Ulta |
| Next Science LLC | $233.79 | 2022-2023 | Blastx, Surgx, Xperience |
| Sanara Medtech INC. | $180.99 | 2023 | Celleraterx |
| Biocomposites INC | $173.57 | 2019 | |
| Linkbio Corp | $136.95 | 2024 | |
| Illuminoss Medical, INC. | $102.11 | 2023 | Photodynamic Bone Stabilization Procedure Pack |
| Baxter Healthcare | $24.73 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $23.65 | 2020 | |
| Smith+Nephew, INC. | $21.10 | 2023 | Pico 14 |
| Pacira Therapeutics, INC. | $18.11 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$0.01 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Gustke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.